Login / Signup

An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States.

Christopher RaspinR Edward FaughtJeanne ArmandFrancesca BarionVicki PollitJoanna MurphyVanessa Danielson
Published in: Journal of medical economics (2023)
VNS was evaluated as a cost effective addition to the current standard of care in the treatment of DRE in the US Medicare context.
Keyphrases
  • drug resistant
  • healthcare
  • multidrug resistant
  • palliative care
  • combination therapy
  • pseudomonas aeruginosa
  • chronic pain
  • replacement therapy